Page 153 - CW E-Magazine (22-4-2025)

Pharmaceuticals

PEPTIDE EXPERTISE

Granules India completes acquisition of Senn Chemicals

Granules India has closed the pre- Synthesis (LPPS) and Solid-Phase next-generation treatments,” Mr. Krishna
viously announced acquisition of Senn Peptide Synthesis (SPPS), serving Prasad Chigurupati, Chairman & Man-
Chemicals AG, a Swiss-based Con- innovators and brand owners across aging Director, Granules India said in
tract Development and Manufacturing pharmaceutical, cosmetic, amino acid a release.
Organisation (CDMO), specialising in derivative (AAD), and theragnostic
peptide development and manufacturing. markets. The acquisition will enable Granules
to accelerate development and manu-
The Hyderabad-based company The Senn Chemicals brand and its facturing of GLP-1 receptor agonists
had earlier signed a defi nitive share operations in Dielsdorf, Switzerland, and other peptide-based APIs, address-
purchase agreement in February 2025, will operate under Granules’ ownership. ing the growing demand in antidiabetic,
through its wholly-owned Indian sub- anti-obesity, and other next-generation
sidiary, Granules Peptides, to acquire “The acquisition of Senn Chemicals therapeutic areas. Granules and Senn
100 percent of the equity of Senn AG marks a pivotal step in Granules’ have already initiated joint development
Chemicals from the founding Senn strategic evolution into a science and activities in this space, with a broader
family for Rs. 192.5-crore. innovation-led organisation. By enter- peptide API pipeline planned. This
ing the rapidly growing peptide thera- transaction also marks Granules’ foray
Founded over 60 years ago, Senn peutics segment and building on Senn’s into the CDMO space, with Senn’s
Chemicals has built a strong reputation specialised CDMO capabilities, we are established CDMO business providing
as a specialist in Liquid-Phase Peptide well positioned to deliver high-quality, a strong platform for growth.

Cipla gets USFDA nod for generic cancer drug

Mumbai-based drug fi rm, Cipla, for injectable suspension
said it has received approval from the 100 mg/vial.
US health regulator to market a generic
cancer treatment drug. Protein-bound paclitaxel
is indicated for the treat-
The company has received the ment of metastatic breast
fi nal approval from the US Food and cancer, locally advanced or
Drug Administration (USFDA) for metastatic non-small cell
the Abbreviated New Drug Applica- lung cancer and metastatic
tion (ANDA) submitted for paclitaxel adenocarcinoma of the
protein-bound particles for inject- pancreas.
able suspension (albumin-bound),
100 mg/vial, single-dose vial, Cipla The product is expected
said in a regulatory fi ling. Cipla’s therapeutic equivalent version of to be launched in the fi rst half of the
protein-bound paclitaxel is a generic Bristol Myers Squibb’s ‘Abraxane’ current fi scal year in the US, Cipla said.

Aurobindo’s US arm gets Form 483 with 11 observations
Aurobindo Pharma said the US tration (USFDA) had conducted These observations are procedural in
health regulator has issued a Form 483 inspection at the plant from March 24, nature,” it added. The company fur-
with 11 observations to the Raleigh 2025, to April 10, 2025, Aurobindo ther said, “We will submit a compre-
plant at North Carolina, USA, owned Pharma said in a regulatory fi ling. hensive response to the USFDA with-
by its arm, Aurolife Pharma LLC. in the stipulated timeline, addressing
“At the conclusion, the USFDA each observation with appropriate
The US Food and Drug Adminis- issued a Form 483 with 11 observations. corrective and preventive actions.”

Chemical Weekly April 22, 2025 153

Contents Index to Advertisers Index to Products Advertised